Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF),[6] also known as B-lymphocyte stimulator (BLyS).[7] It is approved in the United States[8] and Canada,[9] and the European Union[5] to treat systemic lupus erythematosus and lupus nephritis.[10]
The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick).[5]
^"Belimumab (Benlysta) Use During Pregnancy". Drugs.com. 5 February 2020. Archived from the original on 4 December 2020. Retrieved 29 July 2020.
^"BENLYSTA (GlaxoSmithKline Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Retrieved 15 April 2023.
^"Benlysta Product information". Health Canada. 22 October 2009. Retrieved 17 March 2023.
^"Benlysta- belimumab injection, powder, lyophilized, for solution Benlysta- belimumab solution". DailyMed. 17 January 2020. Archived from the original on 25 September 2020. Retrieved 29 July 2020.
^ abc"Benlysta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 25 October 2020. Retrieved 29 July 2020.
^Bossen C, Schneider P (October 2006). "BAFF, APRIL and their receptors: structure, function and signaling" (PDF). Seminars in Immunology. 18 (5): 263–275. doi:10.1016/j.smim.2006.04.006. PMID 16914324.
^Kaveri SV, Mouthon L, Bayry J (September 2010). "Basophils and nephritis in lupus". The New England Journal of Medicine. 363 (11): 1080–1082. doi:10.1056/NEJMcibr1006936. PMID 20825323.
^Cite error: The named reference Manno was invoked but never defined (see the help page).
^DrugBank DB08879
^"Benlysta now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients" (Press release). GlaxoSmithKline. 30 July 2021. Retrieved 17 March 2023 – via Newswire.
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte...
'off-label'. In November 2010, an FDA advisory panel recommended approving belimumab (Benlysta) as a treatment for the pain and flare-ups common in lupus....
and CEO. Benlysta (belimumab) received U.S. Food and Regulatory Administration approval for use in lupus in March 2011. Belimumab was being developed...
mycophenolate, cyclophosphamide, low dose IL-2, intravenous immunoglobulins, and belimumab. Omalizumab is a monoclonal antibody that interacts with the binding site...
first new drug for lupus in more than 50 years to be used in the US, belimumab. In addition to medical therapy, cognitive behavioral therapy has also...
US$3 billion; the companies had collaborated on developing the lupus drug Belimumab (Benlysta), albiglutide for type 2 diabetes, and darapladib for atherosclerosis...
predominantly on the surface of B cells. Like the monoclonal antibody belimumab, atacicept blocks the binding of BLyS, but it also blocks APRIL. Binding...
Adalimumab (Humira) for rheumatoid arthritis and other inflammatory conditions Belimumab (Benlysta) for lupus Cladribine (Leustatin) for hairy cell leukemia Purification...
marketed by Abbvie, formerly Abbott Laboratories. CAT was also behind belimumab, the anti-BlyS antibody drug marketed as Benlysta and the first new approved...
and azathioprine. Newer targeted medications, including omalizumab and belimumab, have also been used. Urticarial vasculitis is featured prominently in...
protocol. She has explored other therapeutics, including voclosporin and belimumab. Alongside development new treatment strategies, Lightstone searched for...
Prophylaxis of acute organ rejection in renal transplant 103764 Link belimumab Benlysta Human Genome Sciences 3/9/2011 intravenous fully human BLyS Systemic...
adalimumab, certolizumab, etanercept, golimumab, infliximab, ixekizumab, belimumab, and ustekinumab. Extracts from some medicinal mushrooms are natural biological...
Global Information
(what is this?) (verify)